Amylin Pharmaceuticals AMLN

… 42%. The FBT ($45.12) First Trust Arca Biotechnology Index Fund is up 38% YTD riding some big winners like Amylin ( AMLN ) Regeneron ( REGN ) and Vertex ( VRTX ). Recently Benziga published an article on biotech ETF's reiterating the …

… March 28 market cap to buyout rumors, biopharma Amylin Pharmaceuticals ( AMLN ) continues to be stubbornly silent on the question ..... ostensibly finding out more about what's going on at Amylin from Bloomberg than they are from their own management …

Wall Street Breakfast Editors submit: Top Stories German recovery helps eurozone avoid recession. German GDP rebounded in Q1 to rise 0.5% on quarter, more than double forecasts of +0.2%, boosted by exports to emerging markets. France showed zero growth and Italy experienced a worse-than-expected ...

Amylin ( AMLN ) has apparently attracted interest from potential suitors including Pfizer ( PFE ), AstraZeneca ( AZN ), Bristol-Myers ( BMY …

By Kapitall : Interested in the growth prospects of the biotech industry? For a closer look at stocks of the biotech sector with positive market sentiment, we ran a screen. We began by screening the biotech industry for stocks currently rallying above their 20-day, 50-day, and 200-day moving ...

By David Pinsen : In a recent blog post ("Can The Crowd Be More Patient?"), venture capitalist Fred Wilson explained the challenge of attracting early equity investment to drug discovery: One of the most noticeable changes to the VC business over the past decade is the movement of investment ...

By Ganaxi Small Cap Movers : Many leading funds, including SAC Capital, MFS and GAMCO, filed forms 13-D and 13-G (and form 4) with the SEC on in the past week-and-a-half (April 25th to May 4th, 2012), indicating that they had amended their ownership in U.S. traded public companies. The following ...

By ValueMax : Eli Lilly ( LLY ) , the $25 billion in sales, pharmaceutical company, is currently at a crossroads which will dictate the future direction of its share price over the next 2 years. Like all drug development companies, future success always depends on the next new blockbuster drug. ...